urea nitrogen after admission (at day 3; odds ratio (per 1 md/ dl): 1.06, 95 % confidence interval (CI) 1.01-1.11, p = 0.02, and at day 7; odds ratio: 1.03, 95 % CI 1.00-1.07, p = 0.03, respectively), and previous stroke (odds ratio; 3.33, 95 % CI 1.01-11.00, p = 0.04). The incidence of ischemic stroke during hospitalization for HF was high, even in patients without AF. Previous stroke and short-term increases in blood urea nitrogen was significantly associated with the incidence of ischemic stroke.
Introduction
Heart failure (HF) is a common and serious disorder with high mortality and morbidity, with an increasing incidence in the elderly [1] . Atrial fibrillation (AF) is common in patients with HF, and it increases the risk of ischemic stroke [2] . However, HF per se is an important risk factor for ischemic stroke [3] . Oral anticoagulants (OAC) were proven to be effective for stroke prevention in AF patients [4] , but there is no generally accepted consensus on OAC treatment for HF patients without AF [5, 6] .
Data from a cohort study indicated that the risk of ischemic stroke is 2-3 times higher for patients with HF than for those without it. The estimated stroke risk in patients with HF was reported to be 1.3-3.9 per 100 patient-years [7] . Notably, recent reports demonstrated that stroke risk is highest within 1 month after the diagnosis of HF [3, 8, 9] . Although the initiation of HF treatment has been considered to be a risk factor for stroke [10] , the underlying mechanism of the increased risk of ischemic stroke after the diagnosis of HF have remained unknown.
It was reported that between 6.5 and 15.0 % of all strokes occur in patients already in hospital, many of whom are there for the treatment of cardiac disorders [11] . However, the incidence of ischemic stroke during hospitalization for HF has not been investigated. Thus, we retrospectively investigated consecutive patients who were hospitalized for HF and investigated the incidence and predictors of ischemic stroke.
Methods

Study design and study population
This is an observational, single-center, retrospective cohort study. The study population consisted of patients with congestive HF, consecutively admitted to Kyoto Medical Center from October 2010 to April 2014. We included patients who were prescribed or added diuretics during the hospitalization for HF. The diagnosis of HF was confirmed based on the Framingham definition of HF [12] by two or more cardiologists at a conference at the cardiology department of the hospital. We excluded patients complicated with the diagnosis of acute myocardial infarction, infective endocarditis, and takotsubo cardiomyopathy. We also excluded patients with dialysis, and those with mechanical circulatory support (intra-aortic balloon pump or extracorporeal membrane oxygenation). Patients' characteristics, co-morbidities, medications, and outcomes were obtained through the electronic medical records. The study protocol was approved by the institutional review boards. Informed consent was waived because the study was conducted in a historical cohort fashion without any intervention and individual identifying information was not used, according to the ethical guidelines for epidemiological research issued by the Ministry of Education, Culture, Sport, Science and Technology and the Ministry of Health, Labor and Welfare, Japan. The investigations were in accordance with the Declaration of Helsinki.
Outcomes
The primary endpoint in this analysis was ischemic stroke during hospitalization for HF. Other endpoints were hemorrhagic stroke, systemic embolism, all-cause death during hospitalization for HF, 30 day mortality rate, and all-cause death during the follow-up period.
Stroke ascertainment and definitions
We identified stroke cases by screening the medical records, and two independent neurologists reviewed the cases and confirmed the diagnoses of stroke. Stroke was defined as the acute onset of a focal neurologic deficit, with computed tomography or magnetic resonance imaging documentation. The underlying ischemic stroke etiology was classified into cardioembolism, large-artery atherosclerosis, small-vessel occlusion, stroke of other determined etiology, and undetermined etiology according to the Trial of Org 10172 Acute Stroke Treatment (TOAST) classification [13] . We did not include strokes found only on brain imaging without correlated clinical symptoms, and catheterrelated strokes. The stroke was considered to be catheterrelated if it occurred during or within 24 h of the cardiac catheterization [14] .
Additional definitions
Systemic embolism was defined as abrupt vascular insufficiency in any peripheral area associated with clinical evidence of arterial occlusion. Co-morbidities such as AF, hypertension, diabetes mellitus, dyslipidemia, history of HF, and history of stroke were defined as clinical documentation of disease at admission for HF. The severity of HF was assessed by the New York Heart Association (NYHA) functional classes. Echocardiography was obtained within 2 weeks of admission. Left ventricular ejection fraction (EF) was calculated by the Teichholz method. Reduced EF was defined as less than 40 %. Local asynergy was defined as any resting local wall motion abnormalities. OAC was defined as warfarin, dabigatran, rivaroxaban, or apixaban. Antiplatelet therapy was defined as the use of aspirin, thienopyridine, or cilostazol. The administration of unfractionated heparin (UFH) was defined as starting UFH on the day of admission. The decision of whether a patient should be treated with antithrombotic drugs was based on the judgment of the attending cardiologist. Data of medications were collected at the time of admission.
Data of body weight were collected at the time of admission, at day 3 (if data were not available, we used data at days 2-5), and at day 7 (if not available, at days 6-10). The laboratory data of hemoglobin, hematocrit, blood urea nitrogen (BUN), and creatinine were also collected at the time of admission, at day 3, and at day 7.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD) or median and interquartile range (IQR). Categorical variables are presented as numbers and percentages. We compared categorical variables using the Chi square test when appropriate; otherwise, we used Fisher's exact test. We compared continuous variables using Student's t test or Wilcoxon rank-sum test on the basis of the distribution. Data were analyzed as crude, stratified by the presence of AF, and by the presence of OAC prescription.
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The Kaplan-Meier method was used to estimate the cumulative incidences of clinical events, and the curves were compared using log-rank test. Thereafter, we analyzed the patients without OAC at admission, to explore the predictors of ischemic stroke. We used JMP software version 10 (SAS Institute, Cary, NC) to perform all of these analyses. Two-sided P values less than 0.05 were considered statistically significant.
Results
A total of 558 consecutive HF patients were enrolled from October 2010 to April 2014. Median length of hospitalization was 18 days (IQR 12-27 days). Median observation period was 393 days (IQR 134-778 days).
Baseline characteristics and co-morbidities in the entire cohort, stratified by the presence of AF, and by the prescription of OAC are shown in Table 1 . The mean age was 76.8 ± 12.3 years. A total of 244 patients (44 %) were female. In addition, 421 patients (75 %) had NYHA III-IV symptoms. The mean left-ventricular EF was 47.4 ± 16.6 %. A total of 271 patients (49 %) had AF (paroxysmal: 14 %, persistent: 6 %, and permanent: 29 %). The median CHADS 2 score was 3 (IQR 2-3.5) in patients with AF. Patients with AF were older and had a higher prevalence of prior stroke. UFH was administered in 97 patients (17 % in the entire cohort, 14 % in patients without AF, and 21 % in patients with AF). OAC was prescribed to 8 (3 %) patients without AF and to 139 (51 %) patients with it. Patients with OAC had higher prevalence of AF, history of HF, and prior stroke.
The major clinical endpoints during hospitalization for HF were as follows (Table 2) : ischemic stroke in 15 (2.7 %), hemorrhagic stroke in 1 (0.2 %), systemic embolism in 1 (0.2 %), and all-cause death in 29 (5.2 %). 30 day mortality rate was 3.9 % (22/558 patients). All stroke cases are shown in Table 3 . None of 15 patients with ischemic stroke was prescribed OAC, whereas 4 patients with ischemic stroke were prescribed antiplatelet drugs. A total of 5 patients with ischemic stroke were given UFH, but activated partial thromboplastin time was not prolonged in 4 patients. Ischemic stroke in 6 of 7 AF patients were caused by cardioembolism, 1 by undermined etiology. Meanwhile, in patients without AF, 2 cases were caused by cardioembolism, 6 by undetermined etiology.
The intervals from the admission of HF to the onset of ischemic stroke are shown in Fig. 1a . The median interval was 10 days (IQR 5 days-17 days). Most of ischemic stroke events occurred at around 1-2 weeks after admission for HF. The Kaplan-Meier curves for all-cause death during the follow-up period are shown in Fig. 1b . Patients complicated with ischemic stroke during hospitalization for HF showed worse prognosis than those without it (hazard ratio: 3.14, 95 % confidence interval (CI) 1.22-6.60).
To explore the predictors of ischemic stroke, we analyzed the patients without OAC at admission (Table 4) . We investigated the impact of baseline characteristics, co-morbidities, and changes of clinical parameters after admission on the incidence of ischemic stroke. History of stroke was significantly associated with a higher incidence of ischemic stroke (odds ratio: 3.33, 95 % CI: 1.01-11.00).
We also explored the impact of decongestion markers, such as changes of body weight, and laboratory data (BUN, creatinine, hemoglobin, and hematocrit) on the incidence of ischemic stroke (Table 5 ). Short-term increases in BUN after admission were associated with increased risk of ischemic stroke (at day 3; odds ratio (per 1 md/dl): 1.06, 95 % CI 1.01-1.11, p = 0.02, and at day 7; odds ratio: 1.03, 95 % CI 1.00-1.07, p = 0.03, respectively). Similarly, those in creatinine were also associated with increased risk of ischemic stroke (at day 3; odds ratio (per 1 md/dl): 4.24, 95 % CI 1.45-11.71, p = 0.01). Other decongestion markers such as in-hospital weight loss and hematocrit change after admission were not associated with increased risk of ischemic stroke. We did not perform the multivariate analysis because of the small number of ischemic stroke events.
Discussion
Incidence of ischemic stroke in patients with HF
HF is an important risk factor for ischemic stroke. The mechanisms leading to increased ischemic stroke in HF may be related to Virchow's triad [15, 16] . First, HF can cause blood flow abnormalities due to the dilatation of cardiac chambers, reduced myocardial contractility, and increased intracardiac and central venous pressure. Second, blood constituent abnormalities can result from platelet and thrombin activation, as a consequence of activation of the sympathetic nervous system and of the renin-angiotensinaldosterone system. Third, HF can also cause vessel wall abnormalities due to inflammation, endothelial dysfunction, and neurohormonal activation.
Underlying mechanism and predictors of ischemic stroke during hospitalization for HF
Interestingly, recent reports demonstrated that stroke risk is highest within 1 month after the diagnosis of HF [3, 8, 9] . The present study showed that the incidence of ischemic stroke was 2.7 % (15/558 patients) during hospitalization for HF (median length: 18 days), which was considerably high compared with previous reports (1.3-3.9 events per 100 patient-years). Our study population was not so different from Japanese large registry of hospitalized HF patients, such as ATTEND Registry [17] , and JCARE-CARD Registry [18] . Why do ischemic stroke events of HF patients predominantly occur during the hospitalization period? Here, we hypothesized and investigated the following mechanisms of increased risk of ischemic stroke during hospitalization for HF. First, the deterioration of HF may increase the blood viscosity and endothelial dysfunction through hypoxia and activation of the sympathetic nervous system [19, 20] . Second, reduced EF or dilated cardiac chamber may cause blood stasis [21] . Third, dehydration after the initiation of diuretics may promote hemoconcentration and hypercoagulation [22] [23] [24] [25] [26] . Severity of HF, such as NYHA functional classes or the presence of hypoxia at admission did not differ between patients with ischemic stroke and those without it. Echocardiographic parameters such as left ventricular EF were not statistically different between the two groups, even if we used another cut off value (EF less than 50 %) or analyzed EF as a continuous variable. However, these results could be due to lack of power considering the small number of the incidence of ischemic stroke (N = 15). Markers of dehydration, such as weight loss, and markers of hemoconcentration, such as hemoglobin or hematocrit, also did not differ between the two groups. Meanwhile, short-term increases in BUN at day 3 or at day 7, and those in creatinine at day 3 were associated with higher incidence of ischemic stroke. Although high serum creatinine was reportedly a risk factor for cerebrovascular events [27] , the significance of the acute increase in creatinine or BUN as a risk factor for stroke in HF patients is unknown, and these issues should be clarified in future studies.
OAC in patients during hospitalization for HF
In our study, none of the patients with OAC was complicated with ischemic stroke, regardless of the presence of All-cause death 29 (5.2 %) 11 (3.8 %) 18 (7.0 %) 0.14 25 (6.1 %) 4 (2.7 %) 0.13 AF. By contrast, 4 patients with antiplatelet therapy, and 5 patients with UFH (given in sub-therapeutic dose in 4 patients) were complicated with ischemic stroke. Moreover, our study showed that the etiology of ischemic stroke during hospitalization for HF was mainly cardioembolism. Although there was no significant difference in composite endpoint of death and stroke between warfarin and aspirin in patients with HF, warfarin treatment was associated with reduced risk of ischemic stroke [6] . Recent case report demonstrated that novel oral anticoagulant was effective treatment for intracardiac thrombus [28, 29] . Given our small sample size, we cannot draw a definite conclusion, but anticoagulation therapy may reduce the risk of ischemic stroke during hospitalization for HF. Further studies are needed to test this hypothesis.
Study limitation
First, this study was a single-center retrospective cohort study, so it was subjected to various biases inherent in such data. Second, antithrombotic prescription was based on the judgment of the attending cardiologist, which may have resulted in selection bias. In fact, anticoagulation was not prescribed to 29 % of AF patients with CHADS 2 score ≥2 points in our study. However, anticoagulation is reportedly underused in daily practice, because physicians often concern about the bleeding complications [30] . Third, stroke predictors in our study were based on only univariate analysis, so it was uncertain whether they were actually independent predictors. The number of patients with ischemic stroke was relatively small, so might be insufficient to perform the multivariate analysis and investigate the mechanisms or associated risk factors precisely. Fourth, we could not investigate the etiology of HF or the existence of cardiogenic shock precisely because of the retrospective fashion, so we could not analyzed the impact of these factors.
Conclusions
The incidence of ischemic stroke during hospitalization for HF was high, even in patients without AF. Previous stroke and short-term increases in BUN was significantly associated with the incidence of ischemic stroke. Considering its 
